Try our Advanced Search for more refined results
UCB, Inc. et al v. Catalent Pharma Solutions Inc. et al
Case Number:
5:21-cv-00038
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
November 29, 2021
Catalent Can't Duck IP Suit Over Epilepsy Drug Vimpat
A Kentucky federal judge on Monday denied a bid to dismiss UCB’s suit against Catalent Pharma Solutions over its importation of the active ingredient in anti-epileptic drug Vimpat, saying the complaint plausibly alleges infringement.
-
May 13, 2021
UCB Can't Halt Drug Ingredient Import In Vimpat IP Case
A Kentucky federal judge refused to block Catalent Pharma Solutions Inc. from importing a key ingredient of the anti-epileptic drug Vimpat, saying the company is protected by a safe harbor provision of the Hatch-Waxman Act.
-
February 08, 2021
Catalent Hit With Patent Suit Over Epilepsy Drug Vimpat
The company that makes the anti-epileptic drug Vimpat has lodged a patent lawsuit against Catalent Pharma Solutions Inc. over allegations that it imported several shipments of a key ingredient to help an Indian drugmaker evade an injunction in an earlier case.